Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in japanese patients? - Rationale and design of the JART study

Masahiko Kurabayashi, Ichiro Sakuma, Ryuzo Kawamori, Hiroyuki Daida, Tsutomu Yamazaki, Masayuki Yoshida, Mitsumasa Hata, Izuru Masuda, Kohei Kaku, Hiroyoshi Yokoi, Junji Kishimoto, Ryuji Nohara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: In Japan, heart disease and cerebral ischemic disease are major causes of death. A decrease in the level of low-density lipoprotein cholesterol (LDL-C) through intensive treatment with statins positively correlates with a reduction in the volume of plaques in patients with cardiovascular disease. The METEOR trial, evaluating the effect of rosuvastatin on carotid intima-media thickness (IMT), was conducted only in Europe and the US. Here we planned another trial, the Justification for Atherosclerosis Regression Treatment (JART) study, to clarify the efficacy of intensive lipid-lowering therapy with rosuvastatin in Japanese with atherosclerosis. Methods and Results: Four hundred patients with hypercholesterolemia (LDL-C ≥140 mg/dL) and a maximum IMT of ≥1.1 mm will be treated for 24 months either with intensive lipid-lowering therapy with rosuvastatin (target LDL-C levels: 80 mg/dL for primary prevention, and 70 mg/dL for secondary prevention) or conventional lipid-lowering therapy with pravastatin (target LDL-C level: complying with JASGL2007). The primary endpoint will be the percent change of mean-IMT and the objectives of the study are to compare the two protocols. Conclusion: The JART trial is a prospective, randomized, open-label, blinded end-point evaluation, multi-center, parallel-group, comparative study to examine the regressive effect of intensive lipid-lowering therapy with statins on atherosclerosis by evaluating IMT in the Japanese population.

Original languageEnglish
Pages (from-to)416-422
Number of pages7
JournalJournal of atherosclerosis and thrombosis
Volume17
Issue number4
DOIs
Publication statusPublished - Jan 1 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Atherosclerosis
Lipids
Pravastatin
Therapeutics
Labels
Carotid Intima-Media Thickness
Primary Prevention
Secondary Prevention
Hypercholesterolemia
Myocardial Ischemia
Cause of Death
Japan
Cardiovascular Diseases
Rosuvastatin Calcium
Population

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Biochemistry, medical

Cite this

Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in japanese patients? - Rationale and design of the JART study. / Kurabayashi, Masahiko; Sakuma, Ichiro; Kawamori, Ryuzo; Daida, Hiroyuki; Yamazaki, Tsutomu; Yoshida, Masayuki; Hata, Mitsumasa; Masuda, Izuru; Kaku, Kohei; Yokoi, Hiroyoshi; Kishimoto, Junji; Nohara, Ryuji.

In: Journal of atherosclerosis and thrombosis, Vol. 17, No. 4, 01.01.2010, p. 416-422.

Research output: Contribution to journalArticle

Kurabayashi, M, Sakuma, I, Kawamori, R, Daida, H, Yamazaki, T, Yoshida, M, Hata, M, Masuda, I, Kaku, K, Yokoi, H, Kishimoto, J & Nohara, R 2010, 'Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in japanese patients? - Rationale and design of the JART study', Journal of atherosclerosis and thrombosis, vol. 17, no. 4, pp. 416-422. https://doi.org/10.5551/jat.2899
Kurabayashi, Masahiko ; Sakuma, Ichiro ; Kawamori, Ryuzo ; Daida, Hiroyuki ; Yamazaki, Tsutomu ; Yoshida, Masayuki ; Hata, Mitsumasa ; Masuda, Izuru ; Kaku, Kohei ; Yokoi, Hiroyoshi ; Kishimoto, Junji ; Nohara, Ryuji. / Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in japanese patients? - Rationale and design of the JART study. In: Journal of atherosclerosis and thrombosis. 2010 ; Vol. 17, No. 4. pp. 416-422.
@article{2fad18a1bf9c442a99f249103ea67e11,
title = "Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in japanese patients? - Rationale and design of the JART study",
abstract = "Aim: In Japan, heart disease and cerebral ischemic disease are major causes of death. A decrease in the level of low-density lipoprotein cholesterol (LDL-C) through intensive treatment with statins positively correlates with a reduction in the volume of plaques in patients with cardiovascular disease. The METEOR trial, evaluating the effect of rosuvastatin on carotid intima-media thickness (IMT), was conducted only in Europe and the US. Here we planned another trial, the Justification for Atherosclerosis Regression Treatment (JART) study, to clarify the efficacy of intensive lipid-lowering therapy with rosuvastatin in Japanese with atherosclerosis. Methods and Results: Four hundred patients with hypercholesterolemia (LDL-C ≥140 mg/dL) and a maximum IMT of ≥1.1 mm will be treated for 24 months either with intensive lipid-lowering therapy with rosuvastatin (target LDL-C levels: 80 mg/dL for primary prevention, and 70 mg/dL for secondary prevention) or conventional lipid-lowering therapy with pravastatin (target LDL-C level: complying with JASGL2007). The primary endpoint will be the percent change of mean-IMT and the objectives of the study are to compare the two protocols. Conclusion: The JART trial is a prospective, randomized, open-label, blinded end-point evaluation, multi-center, parallel-group, comparative study to examine the regressive effect of intensive lipid-lowering therapy with statins on atherosclerosis by evaluating IMT in the Japanese population.",
author = "Masahiko Kurabayashi and Ichiro Sakuma and Ryuzo Kawamori and Hiroyuki Daida and Tsutomu Yamazaki and Masayuki Yoshida and Mitsumasa Hata and Izuru Masuda and Kohei Kaku and Hiroyoshi Yokoi and Junji Kishimoto and Ryuji Nohara",
year = "2010",
month = "1",
day = "1",
doi = "10.5551/jat.2899",
language = "English",
volume = "17",
pages = "416--422",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "4",

}

TY - JOUR

T1 - Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in japanese patients? - Rationale and design of the JART study

AU - Kurabayashi, Masahiko

AU - Sakuma, Ichiro

AU - Kawamori, Ryuzo

AU - Daida, Hiroyuki

AU - Yamazaki, Tsutomu

AU - Yoshida, Masayuki

AU - Hata, Mitsumasa

AU - Masuda, Izuru

AU - Kaku, Kohei

AU - Yokoi, Hiroyoshi

AU - Kishimoto, Junji

AU - Nohara, Ryuji

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Aim: In Japan, heart disease and cerebral ischemic disease are major causes of death. A decrease in the level of low-density lipoprotein cholesterol (LDL-C) through intensive treatment with statins positively correlates with a reduction in the volume of plaques in patients with cardiovascular disease. The METEOR trial, evaluating the effect of rosuvastatin on carotid intima-media thickness (IMT), was conducted only in Europe and the US. Here we planned another trial, the Justification for Atherosclerosis Regression Treatment (JART) study, to clarify the efficacy of intensive lipid-lowering therapy with rosuvastatin in Japanese with atherosclerosis. Methods and Results: Four hundred patients with hypercholesterolemia (LDL-C ≥140 mg/dL) and a maximum IMT of ≥1.1 mm will be treated for 24 months either with intensive lipid-lowering therapy with rosuvastatin (target LDL-C levels: 80 mg/dL for primary prevention, and 70 mg/dL for secondary prevention) or conventional lipid-lowering therapy with pravastatin (target LDL-C level: complying with JASGL2007). The primary endpoint will be the percent change of mean-IMT and the objectives of the study are to compare the two protocols. Conclusion: The JART trial is a prospective, randomized, open-label, blinded end-point evaluation, multi-center, parallel-group, comparative study to examine the regressive effect of intensive lipid-lowering therapy with statins on atherosclerosis by evaluating IMT in the Japanese population.

AB - Aim: In Japan, heart disease and cerebral ischemic disease are major causes of death. A decrease in the level of low-density lipoprotein cholesterol (LDL-C) through intensive treatment with statins positively correlates with a reduction in the volume of plaques in patients with cardiovascular disease. The METEOR trial, evaluating the effect of rosuvastatin on carotid intima-media thickness (IMT), was conducted only in Europe and the US. Here we planned another trial, the Justification for Atherosclerosis Regression Treatment (JART) study, to clarify the efficacy of intensive lipid-lowering therapy with rosuvastatin in Japanese with atherosclerosis. Methods and Results: Four hundred patients with hypercholesterolemia (LDL-C ≥140 mg/dL) and a maximum IMT of ≥1.1 mm will be treated for 24 months either with intensive lipid-lowering therapy with rosuvastatin (target LDL-C levels: 80 mg/dL for primary prevention, and 70 mg/dL for secondary prevention) or conventional lipid-lowering therapy with pravastatin (target LDL-C level: complying with JASGL2007). The primary endpoint will be the percent change of mean-IMT and the objectives of the study are to compare the two protocols. Conclusion: The JART trial is a prospective, randomized, open-label, blinded end-point evaluation, multi-center, parallel-group, comparative study to examine the regressive effect of intensive lipid-lowering therapy with statins on atherosclerosis by evaluating IMT in the Japanese population.

UR - http://www.scopus.com/inward/record.url?scp=77953519925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953519925&partnerID=8YFLogxK

U2 - 10.5551/jat.2899

DO - 10.5551/jat.2899

M3 - Article

VL - 17

SP - 416

EP - 422

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 4

ER -